Biotechnology News and Research

RSS

Cephalon's lawsuit against Teva Pharmaceuticals for patent infringement of NUVIGIL tablets

Cephalon, Inc. today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the "'570 Patent"), 7,297,346 (the "'346 Patent") and RE37,516 (the "'516 Patent") for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV].

3 Dec 2009

Guidelines to diagnose and manage complicated skin and soft tissue infections published

New evidence-based recommendations developed by the Surgical Infection Society to guide physicians in the diagnosis and management of complicated skin and soft tissue infections have been published in Surgical Infections, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

3 Dec 2009

PPD introduces new centralized computing platform for analysis and reporting of clinical trial data

PPD, Inc. today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company’s ability to deliver secure, quality reporting and data analysis to meet client timelines.

2 Dec 2009

Champions Biotechnology and Ramot establish licensing agreement

Champions Biotechnology, Inc., a U.S. Oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

2 Dec 2009

Vitro Diagnostics files a patent application for its technology related to generation of iPS cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the filing of a new United States patent application entitled “POU5-F1 Expression in Human Mesenchymal Stem Cells” and the development of new technology related to generation of human induced pluripotent stem cells (iPS).

2 Dec 2009

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

Phosphagenics Limited today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.

2 Dec 2009

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

Novavax, Inc. today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries.

2 Dec 2009

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

Less than 9 months after implementing a new CRM application, Accera Pharmaceuticals began searching for a replacement. The commercial-stage biotechnology company, which launched Axona™ (a prescription-only medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease) around the same time as it implemented its current system, had quickly outgrown the generic CRM tool.

2 Dec 2009

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration.

2 Dec 2009

Genzyme ships vials of newly produced Cerezyme

Genzyme Corporation announced today that it has begun shipping vials of newly produced Cerezyme® (imiglucerase for injection) manufactured at its Allston Landing plant.

2 Dec 2009

Future likely to witness improved therapies and novel drugs to treat lifestyle disorders

Increasing genomic knowledge will lead to the development of improved therapies to treat lifestyle disorders. In the near future, the European lifestyle disorders therapeutics market is set to witness enhanced therapies and novel drugs to treat such conditions and reduce the risk of co-morbidities.

2 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

2 Dec 2009

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

Ohr Pharmaceutical Inc., announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.

2 Dec 2009

Stem Cell Therapy International and Histostem sign distribution agreement

Stem Cell Therapy International Inc. (OTCBB: SCII) announced that it has signed an agreement with Histostem Ltd. of South Korea ("Histostem"), for the exclusive, worldwide rights to the distribution of the Company's existing SteMixx line of stem cell based cosmetic products, as well as future products under development. Previously available for purchase only in Korea, SteMixx received approval last month from the Korean FDA as an effective cosmetic for the treatment of aging skin.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Ardea Biosciences, Inc. announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This

1 Dec 2009

MAbs for early detection of cancer

Two sets of recommendations issued earlier this month have revised longstanding guidelines concerning the age at which women should first be tested for breast and cervical cancer and how frequently.

1 Dec 2009

Biotechnology News and Research

Cephalon's lawsuit against Teva Pharmaceuticals for patent infringement of NUVIGIL tablets

Guidelines to diagnose and manage complicated skin and soft tissue infections published

PPD introduces new centralized computing platform for analysis and reporting of clinical trial data

Champions Biotechnology and Ramot establish licensing agreement

Vitro Diagnostics files a patent application for its technology related to generation of iPS cells

Phosphagenics commences Phase 1B clinical trial of its oxycodone/TPM transdermal patch systems

Favorable initial results from Novavax' 2009 H1N1 VLP pandemic influenza vaccine Phase II study

Accera Pharmaceuticals to implement the Veeva CRM suite of multi-tenant SaaS applications

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Genzyme ships vials of newly produced Cerezyme

Future likely to witness improved therapies and novel drugs to treat lifestyle disorders

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

DiaMedica to acquire all issued and outstanding shares of Sanomune

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

Stem Cell Therapy International and Histostem sign distribution agreement

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

MAbs for early detection of cancer

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News